The AMSP drug safety program:: Methods and global results

被引:107
|
作者
Grohmann, R
Engel, RR
Rüther, E
Hippius, H
机构
[1] Univ Munich, Psychiat Klin, Dept Psychiat, D-80336 Munich, Germany
[2] Univ Gottingen, Dept Psychiat, D-3400 Gottingen, Germany
关键词
D O I
10.1055/s-2004-815505
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The AMSP (Arzneimittelsicherheit in der Psychiatry) study is a drug safety program that ensures the continuous assessment of severe adverse drug reactions (ADR) in psychiatric inpatients under the natural conditions Of routine clinical treatment. It developed out of the preceding drug surveillance study AMUP (Arzneimitteluberwachung in der Psychiatrie). Currently 35 hospitals participate in the Study. This paper describes the methods of the AMSP, gives detailed definitions of ADRs assessed to be "severe," and discusses the implications of these definitions and the methodological approach for evaluating the AMSP data. In addition, some overall data compiled on ADR rates from 1993 to 2000 are given.
引用
收藏
页码:S4 / S11
页数:8
相关论文
共 50 条
  • [21] Extrapyramidal reactions following treatment with antidepressants: Results of the AMSP multinational drug surveillance programme
    Moerkl, Sabrina
    Seltenreich, Daniel
    Letmaier, Martin
    Bengesser, Susanne
    Wurm, Walter
    Grohmann, Renate
    Bleich, Stefan
    Toto, Sermin
    Stuebner, Susanne
    Butler, Mary I.
    Kasper, Siegfried
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2020, 21 (04): : 308 - 316
  • [22] Age and adverse effects of psychopharmacological treatment. data from the drug surveillance program amsp in switzerland
    Greil, W.
    Haeberle, A.
    Schuhmann, T.
    Grohmann, R.
    Baumann, P.
    EUROPEAN PSYCHIATRY, 2013, 28
  • [23] Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP
    Haeberle, Anne
    Greil, Waldemar
    Russmann, Stefan
    Grohmann, Renate
    BMC PSYCHIATRY, 2012, 12
  • [24] Atypical dyskinesias under treatment with antipsychotic drugs: Report from the AMSP multicenter drug safety project
    Baumgaertner, Jessica
    Grohmann, Renate
    Bleich, Stefan
    Glocker, Catherine
    Seifert, Johanna
    Toto, Sermin
    Ruether, Eckart
    Engel, Rolf R.
    Stuebner, Susanne
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2022, 23 (02): : 151 - 164
  • [25] Clozapine-Induced DRESS Syndrome: A Case Series From the AMSP Multicenter Drug Safety Surveillance Project
    Sanader, Bruna
    Grohmann, Renate
    Groetsch, Philipp
    Schumann, Thomas
    Toto, Sermin
    Fernando, Piyumi
    Stuebner, Susanne
    PHARMACOPSYCHIATRY, 2019, 52 (03) : 156 - 159
  • [26] Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program
    Konstantinidis, A.
    Papageorgiou, K.
    Grohmann, R.
    Horvath, A.
    Engel, R.
    Kasper, S.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 (04): : 449 - 457
  • [27] Statistical methods for drug safety
    Wang, William
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2016, 26 (05) : 1003 - 1004
  • [28] Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP
    Anne Haeberle
    Waldemar Greil
    Stefan Russmann
    Renate Grohmann
    BMC Psychiatry, 12
  • [29] DRUG SAFETY PROGRAM FOR AURANOFIN (RIDAURA)
    HABS, M
    MISSLER, B
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 1984, 43 (04): : 227 - 227
  • [30] Suicidality as Rare Adverse Event of Antidepressant Medication: Report From the AMSP Multicenter Drug Safety Surveillance Project
    Stuebner, Susanne
    Grohmann, Renate
    von Stralendorff, Irmela
    Ruether, Eckart
    Moeller, Hans-Juergen
    Mueller-Oerlinghausen, Bruno
    Engel, Rolf R.
    Horvath, Andreas
    Greil, Waldemar
    JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (10) : 1293 - 1307